GSK (LSE:GSK) has licensed worldwide rights to its experimental liver disease drug linerixibat to Alfasigma. The agreement covers development and commercialization of linerixibat as GSK reallocates ...

Feb 25 (Reuters) - GSK has agreed to pay $950 million in cash for Canadian biotech 35Pharma, it said on Wednesday, marking ...

"We are excited to establish the agreement with GSK, a global biopharma company. It reflects the growing recognition of our R&D capabilities. This agreement will solidify a robust foundation for ...

Chinese drugmaker Jiangsu Hengrui Pharmaceuticals has agreed to develop up to 12 of its drugs with British pharmaceutical giant GSK. Hengrui Pharma granted GSK an exclusive worldwide licence to its ...

GSK (LSE:GSK) has completed its acquisition of RAPT Therapeutics, securing global rights to key immunology assets. The deal brings ozureprubart, a monoclonal antibody for severe food allergies, into ...

A major pharmaceutical company is leaving behind more than half a million square feet in a suburb of Washington, D.C. when its lease expires next year. London-based GSK is set to depart 635,000 square ...

Delve into the field of pulmonary hypertension as GSK places a $950M bet on 35Pharma's candidate HS235 following the footsteps of Winrevair.